Craft

Genematrix

Stock Price

₩3.4 K

2024-10-29

Market Capitalization

₩65.7 B

2024-10-29

Revenue

₩9.8 B

FY, 2023

Genematrix Summary

Company Summary

Overview
Genematrix is a company that develops molecular diagnostic products. Its core platform technologies (C-TAG, Omniplex, EnCleap, TriO, and REMP) focus on various diseases, such as hepatitis B, hepatitis C, cervical cancer, sexually transmitted infections, respiratory infections, and more. In addition to detection kits, the company develops vaccines as well as natural pharmaceutical materials for health improvement or treatment.
Type
Public
Status
Active
Founded
2000
HQ
Seongnam-si, KR | view all locations
Website
http://www.genematrix.net/
Cybersecurity rating
Sectors

LocationsView all

1 location detected

  • Seongnam-si, Gyeonggi-do HQ

    Korea (Republic of)

    700 Daewangpangyo-ro, Sampyeong-dong, Bundang-gu

Genematrix Financials

Summary Financials

Revenue (Q3, 2024)
₩2.6B
Gross profit (Q3, 2024)
₩1.7B
Net income (Q3, 2024)
(₩193.4M)
Cash (Q3, 2024)
₩1.6B
EBIT (Q3, 2024)
(₩115.1M)
Enterprise value
$67.7B

Footer menu